A Study of APG-3288 in Relapsed/Refractory Blood Cancers
← catalyst calendarNCT07424833 · readout ≤ 1,230 d
Sponsored by Ascentage Pharma Group Inc. (industry) · AAPG — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
180estimated
Sites
6
Countries
China, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Aug 2026 | estimated | When the study began enrolling |
| Primary completion | Dec 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2031 | estimated | The whole study's end, after follow-up |
| First posted | 2026-02-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Relapsed/Refractory Hematological Malignancies
- Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL
- Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL; Including Richter Transformation)
- Relapsed/Refractory Mantle Cell Lymphoma (MCL)
- Relapsed/Refractory Waldenström Macroglobulinemia (WM)
- Relapsed/Refractory Marginal Zone Lymphoma (MZL)
- Relapsed/Refractory Follicular Lymphoma (FL)
Intervention
- Drug: APG-3288
Primary outcomes
what the primary-completion date above is the date OFIncidence of dose-limiting toxicities (DLTs) at each dose level
measured From first dose through the end of Cycle 1 (e.g., Day 1 to Day 28)
Incidence of treatment emergent adverse events (TEAEs)
measured From first dose of study treatment through 30 days after the last dose
Maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of APG 3288
measured During the dose escalation phase (Part 1)
Permalink · AAPG's whole pipeline · Catalyst calendar · Every registered study · What changed